1. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2020;70(4):313.
2. Yang Y, Hong P, Xu W, He Q, Li B. Advances in targeted therapy for esophageal cancer. Signal transduction and targeted therapy. 2020;5(1):229.
3. Gao H, Shen W, Zhang X, Xu J, Li Y, Li S, et al. Preliminary analysis of the benefits of different irradiation types on patients with postoperative locoregional recurrence of esophageal cell squamous carcinoma. Annals of palliative medicine. 2021;10(9):9467-79.
4. Guo X, Meng X, Liu R. Prognostic value of microvessel density in esophageal squamous cell carcinoma-a systematic review and meta-analysis. Pathology, research and practice. 2021;227:153644.
5. Zhang X, Lu N, Wang L, Wang Y, Li M, Zhou Y, et al. Recent advances of mA methylation modification in esophageal squamous cell carcinoma. Cancer cell international. 2021;21(1):421.
6. Arnold M, Ferlay J, van Berge Henegouwen M, Soerjomataram I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69(9):1564-71.
7. Zhang W, Yan C, Zhang T, Chen X, Dong J, Zhao J, et al. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study. Oncoimmunology. 2021;10(1):1971418.
8. Visaggi P, Barberio B, Ghisa M, Ribolsi M, Savarino V, Fassan M, et al. Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence. Cancers. 2021;13(13).
9. Yuan Z, Wang X, Geng X, Li Y, Mu J, Tan F, et al. Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible? Cancer communications (London, England). 2021;41(1):3-15.
10. Chetwood J, Garg P, Finch P, Gordon M. Systematic review: the etiology of esophageal squamous cell carcinoma in low-income settings. Expert review of gastroenterology & hepatology. 2019;13(1):71-88.
11. Yamamoto Y, Kadota T, Yoda Y, Hori K, Hatogai K, Kojima T, et al. Review of early endoscopic findings in patients with local recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Esophagus : official journal of the Japan Esophageal Society. 2020;17(4):433-9.
12. Wang Y, Lu Y, Xu W, Wang Y, Wu Y, Che G. Prognostic value of osteopontin expression in esophageal squamous cell carcinoma: A meta-analysis. Pathology, research and practice. 2019;215(10):152571.
13. Bull A, Pucher P, Lagergren J, Gossage J. Chest drainage after oesophageal resection: A systematic review. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2021.
14. Paiboonrungruang C, Simpson E, Xiong Z, Huang C, Li J, Li Y, et al. Development of targeted therapy of NRF2 esophageal squamous cell carcinoma. Cellular signalling. 2021:110105.
15. Puhr H, Preusser M, Ilhan-Mutlu A. Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021? Cancers. 2021;13(18).
16. Zhang H, Si J, Yue J, Ma S. The mechanisms and reversal strategies of tumor radioresistance in esophageal squamous cell carcinoma. Journal of cancer research and clinical oncology. 2021;147(5):1275-86.
17. Jin Z, Chen D, Chen M, Wang C, Zhang B, Zhang J, et al. (Neo)adjuvant Chemoradiotherapy is Beneficial to the Long-term Survival of Locally Advanced Esophageal Squamous Cell Carcinoma: A Network Meta-analysis. World journal of surgery. 2021.
18. Thakur B, Devkota M, Chaudhary M. Management of Locally Advanced Esophageal Cancer. JNMA; journal of the Nepal Medical Association. 2021;59(236):409-16.
19. Chen L, Wei Q, Bi S, Xie S. Maternal Embryonic Leucine Zipper Kinase Promotes Tumor Growth and Metastasis via Stimulating FOXM1 Signaling in Esophageal Squamous Cell Carcinoma. Frontiers in oncology. 2020;10:10.
20. Pal-Ghosh R, Xue D, Warburton R, Hill N, Polgar P, Wilson J. CDC2 Is an Important Driver of Vascular Smooth Muscle Cell Proliferation via FOXM1 and PLK1 in Pulmonary Arterial Hypertension. International journal of molecular sciences. 2021;22(13).
21. Li Y, Wu F, Tan Q, Guo M, Ma P, Wang X, et al. The multifaceted roles of FOXM1 in pulmonary disease. Cell communication and signaling : CCS. 2019;17(1):35.
22. Wei Y, Wang Z, Zong Y, Deng D, Chen P, Lu J. LncRNA MFI2-AS1 promotes HCC progression and metastasis by acting as a competing endogenous RNA of miR-134 to upregulate FOXM1 expression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020;125:109890.
23. Zhao P, Li T, Wang Y, Wang Y, Gu Q, Li Z. LncRNA MYCNOS promotes glioblastoma cell proliferation by regulating miR-216b/FOXM1 axis. Metabolic brain disease. 2021;36(6):1185-9.
24. Goodman A, Mahmud W, Buckingham L. Gene variant profiles and tumor metabolic activity as measured by FOXM1 expression and glucose uptake in lung adenocarcinoma. Journal of pathology and translational medicine. 2020;54(3):237-45.
25. Ai C, Zhang J, Lian S, Ma J, Győrffy B, Qian Z, et al. FOXM1 functions collaboratively with PLAU to promote gastric cancer progression. Journal of Cancer. 2020;11(4):788-94.
26. Kalathil D, John S, Nair A. FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis. Frontiers in oncology. 2020;10:626836.
27. Su M, Tang J, Zhang B, Yang D, Wu Z, Wu J, et al. LncRNA GACAT3 promotes esophageal squamous cell carcinoma progression through regulation of miR-149/FOXM1. Cancer cell international. 2021;21(1):478.
28. Cheng L, Wang Q, Tao X, Qin Y, Wu Q, Zheng D, et al. FOXM 1 induces Vasculogenic mimicry in esophageal cancer through β-catenin /Tcf4 signaling. Diagnostic pathology. 2020;15(1):14.
29. Xiao Z, Jia Y, Jiang W, Wang Z, Zhang Z, Gao Y. FOXM1: A potential indicator to predict lymphatic metastatic recurrence in stage IIA esophageal squamous cell carcinoma. Thoracic cancer. 2018;9(8):997-1004.
30. Li G, Yang L, Chen G, Huang S, Fang Y, Huang W, et al. Laryngeal Squamous Cell Carcinoma: Clinical Significance and Potential Mechanism of Cell Division Cycle 45. Cancer biotherapy & radiopharmaceuticals. 2021.
31. Huang W, Chen G, Chen S, Dang Y, Deng Y, Zhou H, et al. The Indication of Poor Prognosis by High Expression of ENO1 in Squamous Cell Carcinoma of the Lung. Journal of oncology. 2021;2021:9910962.
32. He R, Li J, Du X, Dang Y, Yang L, Huang Z, et al. LPCAT1 overexpression promotes the progression of hepatocellular carcinoma. Cancer cell international. 2021;21(1):442.
33. Chen S, Zhou H, Zhang H, He R, Huang Z, Dang Y, et al. PTTG1The Clinical Significance and Potential Molecular Mechanism of in Esophageal Squamous Cell Carcinoma. Frontiers in genetics. 2020;11:583085.
34. Li R, Chen G, Dang Y, He R, Liu A, Ma J, et al. Expression and Clinical Significance of BCL2 Interacting Protein 3 Like in Multiple Myeloma. Technology in cancer research & treatment. 2021;20:15330338211024551.
35. Gao L, Pang Y, Guo X, Zeng J, Tang Z, Xiong D, et al. Polo like kinase 1 expression in cervical cancer tissues generated from multiple detection methods. PeerJ. 2020;8:e10458.
36. Yang D, Huang W, Chen G, Chen S, Yang J, He R, et al. Clinical significance of transcription factor RUNX2 in lung adenocarcinoma and its latent transcriptional regulating mechanism. Computational biology and chemistry. 2020;89:107383.
37. Pang Y, Li J, Gao L, Yang X, Dang Y, Lai Z, et al. The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues. Cancer medicine. 2020;9(21):8004-19.
38. Yuan Y, Wang Q, Cao F, Han B, Xu L. MiRNA-134 suppresses esophageal squamous cell carcinoma progression by targeting FOXM1. International journal of clinical and experimental pathology. 2019;12(6):2130-8.
39. Nicolau-Neto P, Da Costa N, de Souza Santos P, Gonzaga I, Ferreira M, Guaraldi S, et al. FOXM1Esophageal squamous cell carcinoma transcriptome reveals the effect of on patient outcome through novel PIK3R3 mediated activation of PI3K signaling pathway. Oncotarget. 2018;9(24):16634-47.
40. Song L, Wang X, Feng Z. Overexpression of FOXM1 as a target for malignant progression of esophageal squamous cell carcinoma. Oncology letters. 2018;15(4):5910-4.
41. Takata A, Takiguchi S, Okada K, Takahashi T, Kurokawa Y, Yamasaki M, et al. Clinicopathological and prognostic significance of FOXM1 expression in esophageal squamous cell carcinoma. Anticancer research. 2014;34(5):2427-32.
42. Hui M, Chan K, Luk J, Lee N, Chung Y, Cheung L, et al. Cytoplasmic Forkhead box M1 (FoxM1) in esophageal squamous cell carcinoma significantly correlates with pathological disease stage. World journal of surgery. 2012;36(1):90-7.
43. Yang D, Ma Y, Zhao P, Ma J, He C. HMMR is a downstream target of FOXM1 in enhancing proliferation and partial epithelial-to-mesenchymal transition of bladder cancer cells. Experimental cell research. 2021:112860.
44. Liu C, Barger C, Karpf A. FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer. Cancers. 2021;13(12).
45. Wang X, Dou N, Wang J, Zhang Y, Li Y, Gao Y. FOXM1-induced miR-552 expression contributes to pancreatic cancer progression by targeting multiple tumor suppressor genes. International journal of biological sciences. 2021;17(4):915-25.
46. Ma X, Zhang H, Li Q, Schiferle E, Qin Y, Xiao S, et al. viaFOXM1 Promotes Head and Neck Squamous Cell Carcinoma Activation of the Linc-ROR/LMO4/AKT/PI3K Axis. Frontiers in oncology. 2021;11:658712.
47. Kaochar S, Rusin A, Foley C, Rajapakshe K, Robertson M, Skapura D, et al. Inhibition of GATA2 in prostate cancer by a clinically available small molecule. Endocrine-related cancer. 2021.
48. Wang Q, Zhong W, Deng L, Lin Q, Lin Y, Liu H, et al. The Expression and Prognostic Value of SUMO1-Activating Enzyme Subunit 1 and Its Potential Mechanism in Triple-Negative Breast Cancer. Frontiers in cell and developmental biology. 2021;9:729211.
49. Yoshida T, Ohe C, Ikeda J, Atsumi N, Saito R, Taniguchi H, et al. Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma. The journal of pathology Clinical research. 2021.
50. Qi H, Wang L, Zhang X, Sun W, Liu J. LncRNA SBF2-AS1 inhibits apoptosis and promotes proliferation in lung cancer cell via regulating FOXM1. Journal of BUON : official journal of the Balkan Union of Oncology. 2020;25(4):1761-70.
51. Wu C, Yeh C, Lin K. Thyroid hormones suppress FOXM1 expression to reduce liver cancer progression. Oncology reports. 2020;44(4):1686-98.
52. Li S, Liu N, Piao J, Meng F, Li Y. CCNB1 Expedites the Progression of Cervical Squamous Cell Carcinoma via the Regulation by FOXM1. OncoTargets and therapy. 2020;13:12383-95.
53. Yu H, Zhang S, Ibrahim A, Deng Z, Wang M. Serine/threonine kinase BUB1 promotes proliferation and radio-resistance in glioblastoma. Pathology, research and practice. 2019;215(8):152508.
54. Xia M, Zhang Q, Luo M, Li P, Wang Y, Lei Q, et al. Regulatory network analysis reveals the oncogenesis roles of feed-forward loops and therapeutic target in T-cell acute lymphoblastic leukemia. BMC medical genomics. 2019;12(1):8.
55. Lee H, Chu K, Moon E, Quan F. Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells via Forkhead Box M1 Suppression. Journal of Cancer. 2021;12(17):5086-98.
56. Lee N, Kim D, Jin H, Meng R, Chae O, Kim S, et al. Inactivation of the Akt/FOXM1 Signaling Pathway by Panobinostat Suppresses the Proliferation and Metastasis of Gastric Cancer Cells. International journal of molecular sciences. 2021;22(11).
57. Shi T, Sun W, Shi Y, Wang Q, Yan Z, Zhang M. LncRNA OSER1-AS1 interacts with miR-612/FOXM1 axis to modulate gefitinib resistance of lung adenocarcinoma. American journal of translational research. 2021;13(3):1365-76.
58. Nicolau-Neto P, Palumbo A, De Martino M, Esposito F, de Almeida Simão T, Fusco A, et al. UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1. Genes. 2018;9(4).